Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PRME 
Prime Medicine, Inc. Common Stock (PRME)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/23/2025: PRME (1-star) is a SELL. SELL since 1 days. Simulated Profits (15.20%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $6.5
1 Year Target Price $6.5
| 6 | Strong Buy |
| 2 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -34.95% | Avg. Invested days 26 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/23/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 910.98M USD | Price to earnings Ratio - | 1Y Target Price 6.5 |
Price to earnings Ratio - | 1Y Target Price 6.5 | ||
Volume (30-day avg) 12 | Beta 2.67 | 52 Weeks Range 1.11 - 6.94 | Updated Date 10/23/2025 |
52 Weeks Range 1.11 - 6.94 | Updated Date 10/23/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.56 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-10-31 | When - | Estimate -0.43 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -4787.18% |
Management Effectiveness
Return on Assets (TTM) -47.39% | Return on Equity (TTM) -154.81% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1207073566 | Price to Sales(TTM) 183.63 |
Enterprise Value 1207073566 | Price to Sales(TTM) 183.63 | ||
Enterprise Value to Revenue 243.31 | Enterprise Value to EBITDA -3.1 | Shares Outstanding 178273998 | Shares Floating 74714717 |
Shares Outstanding 178273998 | Shares Floating 74714717 | ||
Percent Insiders 18.19 | Percent Institutions 44.37 |
Upturn AI SWOT
Prime Medicine, Inc. Common Stock
Company Overview
History and Background
Prime Medicine, Inc. was founded in 2020, pioneering prime editing technology, a next-generation gene editing approach. The company aims to develop therapies for a broad range of diseases by precisely correcting disease-causing genes.
Core Business Areas
- Prime Editing Platform Development: Developing and optimizing the prime editing technology platform for therapeutic applications.
- Therapeutic Programs: Advancing a pipeline of therapeutic programs targeting various genetic diseases. Initial focus areas include liver, eye, ex-vivo hematopoietic stem cells and neuromuscular disorders.
- Partnerships and Licensing: Establishing strategic partnerships and licensing agreements to expand the application of prime editing technology.
Leadership and Structure
Keith Gottesdiener, M.D., is the CEO. The company has a leadership team with expertise in gene editing, drug development, and business strategy. The organizational structure is focused on research and development, with dedicated teams for platform development and therapeutic programs.
Top Products and Market Share
Key Offerings
- Prime Editing Technology: Prime editing is a gene editing technology designed to correct disease-causing mutations in a precise and efficient manner. It is currently in the pre-clinical stage of development. Competitors include companies developing CRISPR-based gene editing technologies such as CRISPR Therapeutics (CRSP) and Intellia Therapeutics (NTLA).
- Pre-clinical Therapeutic Programs: Prime Medicine is advancing pre-clinical programs targeting various genetic diseases, including liver, eye, and neuromuscular disorders. Since the technology is in pre-clinical stages there is no revenue from those products. Competitors depend on the target disease, but includes Vertex Pharmaceuticals (VRTX) for genetic diseases.
Market Dynamics
Industry Overview
The gene editing industry is rapidly evolving, driven by advancements in technologies like CRISPR and prime editing. There is high demand for precise and efficient gene editing tools with broad therapeutic applications.
Positioning
Prime Medicine is positioned as a leader in prime editing technology. Its competitive advantage lies in the potential for greater precision and versatility compared to other gene editing methods.
Total Addressable Market (TAM)
The TAM for gene editing therapies is estimated to be in the tens of billions of dollars, driven by the potential to treat a wide range of genetic diseases. Prime Medicine aims to capture a significant portion of this market with its prime editing technology.
Upturn SWOT Analysis
Strengths
- Proprietary prime editing technology
- Strong intellectual property position
- Experienced leadership team
- Significant funding and partnerships
Weaknesses
- Technology is still in early stages of development
- High research and development costs
- Reliance on partnerships for commercialization
- Limited clinical data
Opportunities
- Expanding therapeutic applications of prime editing
- Securing additional partnerships and licensing agreements
- Advancing therapeutic programs into clinical trials
- Developing improved delivery methods for prime editing
Threats
- Competition from other gene editing technologies
- Regulatory hurdles for gene editing therapies
- Potential safety concerns associated with gene editing
- Intellectual property disputes
Competitors and Market Share
Key Competitors
- CRSP
- NTLA
- EDIT
- BEAM
Competitive Landscape
Prime Medicine faces strong competition from companies developing CRISPR-based gene editing technologies. However, Prime Medicine's prime editing technology offers the potential for greater precision and versatility.
Growth Trajectory and Initiatives
Historical Growth: Since inception in 2020 there has been no revenue. Growth relates to technological advancement.
Future Projections: Future growth is dependent on successful advancement of therapeutic programs into clinical trials and securing partnerships.
Recent Initiatives: Prime Medicine is focused on advancing its pipeline of therapeutic programs and expanding the applications of its prime editing technology.
Summary
Prime Medicine is an early-stage company pioneering prime editing technology. The company has a strong intellectual property position and is well-funded. However, the technology is still in early stages of development, and the company faces strong competition and regulatory hurdles. Future success depends on advancing therapeutic programs into clinical trials and securing partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Prime Medicine's SEC Filings
- Company Website
- Analyst Reports
- Market Research Reports
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. The information is based on publicly available data and analyst estimates, which are subject to change. Investing in biotechnology companies carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Prime Medicine, Inc. Common Stock
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2022-10-20 | CEO & Director Dr. Allan Reine M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 214 | Website https://primemedicine.com |
Full time employees 214 | Website https://primemedicine.com | ||
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.